Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - rasagilinum - compresse - rasagilinum 1 mg a rasagilini tartras, excipiens pro compresso. - morbo di parkinson - synthetika

Европейски съюз - италиански - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenti antineoplastici - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Европейски съюз - италиански - EMA (European Medicines Agency)

mylan ireland limited - il triossido di arsenico - leucemia, promielocitica, acuta - agenti antineoplastici - il triossido di arsenico mylan è indicato per l'induzione della remissione e di consolidamento in pazienti adulti con:- di nuova diagnosi in basso a intermedio rischio di leucemia promielocitica acuta (apl) (numero di globuli bianchi, ≤ 10 x 103/µl) in combinazione con acido all trans retinoico (atra)- recidivato/refrattario leucemia promielocitica acuta (apl) (precedente trattamento che deve aver incluso un retinoide e chemioterapia), caratterizzata dalla presenza di t(15;17) traslocazione e/o la presenza di leucemia promielocitica/recettore dell'acido retinoico alfa (pml/rar alfa) gene. il tasso di risposta di altri mieloide acuta leucemia sottotipi di triossido di arsenico non ha beenexamined.

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - torasemidum - compresse - torasemidum 2.5 mg, lactosum monohydricum 60,5 mg, maydis per amylum, silice colloidalis anhydrica, magnesio stearas, pro compresso. - diureticum - synthetika

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - torasemidum - compresse - torasemidum 5 mg, lactosum monohydricum 58 mg, maydis per amylum, silice colloidalis anhydrica, magnesio stearas, pro compresso. - diureticum - synthetika

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - torasemidum - compresse - torasemidum 10 mg, lactosum monohydricum 116 mg, maydis per amylum, silice colloidalis anhydrica, magnesio stearas, pro compresso. - diureticum - synthetika

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - torasemidum - compresse - torasemidum 200 mg, lactosum monohydricum 97 mg, crospovidonum, povidonum, magnesio stearas, cellulosum microcristallinum, pro compresso. - diureticum - synthetika

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - agomelatinum - compresse rivestite con film - agomelatinum 25 mg ut agomelatinum-acidum citricum, cellulosum microcristallinum silicificatum, mannitolum, povidonum k 30, silica colloidalis anhydrica, crospovidonum, natrii stearylis fumaras corresp. natrium 0.2 mg, magnesii stearas, acidum stearicum, Überzug: hypromellosum, macrogolum 6000, talcum, e 171, e 172 (flavum) pro compresso obducto. - antidepressivo - synthetika

Швейцария - италиански - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - dienogestum - compresse - dienogestum 2.00 mg, lactosum monohydricum 60.93 mg, maydis per amylum, povidonum k 30, magnesio stearas, pro compresso. - trattamento dell'endometriosi - synthetika

Европейски съюз - италиански - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.